David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Qualcomm Stock Will Easily Pierce Through $100 With Earnings on Deck

By David Moadel, InvestorPlace Contributor

This week's highly anticipated earnings announcement is exactly what Qualcomm stock needs to shatter a long-standing resistance level.

Pricey Shopify Stock Represents What’s Wrong With the Stock Market

By David Moadel, InvestorPlace Contributor

Now does not look like the time to buy Shopify stock, as valuations outpace fundamentals in this wacky market environment.

General Motors’ Next-Gen Vehicles Will Help the Stock Cruise Higher

By David Moadel, InvestorPlace Contributor

General Motors is taking aim at its rivals with its Cruise line of offerings. Could this lift GM stock out of the doldrums?

3 Great Healthcare Stocks to Buy Right Now

By David Moadel, InvestorPlace Contributor

The sector is a safe bet for long-term growth, but which health-care stocks stand to gain the most? Here are three picks to consider today.

Ocugen Is a Bold Biotech Bet, But the Payoff Could Be Rich

By David Moadel, InvestorPlace Contributor

A pipeline of treatments for underserved eye conditions like oGVHD makes OCGN stock worth considering as part of your biotech holdings.

Load More